Bone metastasis is strongly associated with estrogen receptor–positive/progesterone receptor–negative breast carcinomas

Wei, Bing; Wang, Jianmin; Bourne, Patricia A.; Yang, Qi; Hicks, David G.; Bu, Hong; Tang, Ping

doi:10.1016/j.humpath.2008.05.010

Cited by 57 publications

(60 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent study, it was reported that BM are more likely to occur in patients with HER-2-expressing tumors [25]. In contrast, other authors have reported that the majority of patients who present bone relapse have ER-positive tumors and that there seems to be no association between HER-2 expression of primary breast cancer and bone relapse [29]. Moreover, recent studies using in vitro and in vivo breast cancer experimental models have shown that BM might not occur unless specific genes are expressed and act in cooperation with numerous protein products [23,27,28].…”

Section: Discussionmentioning

confidence: 99%

The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study

et al. 2011

View full text Add to dashboard Cite

Objective: The chemokine receptor CXCR4 is involved in tumor growth and homing of cancer cells to distant sites. The aim of our retrospective case-control study was to evaluate whether CXCR4 expression is more effective than conventional markers (estrogen receptor and HER-2) in predicting bone relapse in breast cancer. Methods: CXCR4 expression was evaluated by immunohistochemical staining in paraffin-embedded tissue sections of primary breast cancers from 20 patients with bone metastases (BM), 10 with visceral metastases (VM) and 10 with no evidence of disease (NED) at a median follow-up of 10.5 years (range 10.1–11.8). Results: Cytoplasmic CXCR4 expression was high in BM patients (45%, 95% CI 23–67), much lower in NED patients (10%, 95% CI 0–29) and negative in the VM group. CXCR4 coexpression in the nucleus and cytoplasm was observed in about half of the BM patients (45%) but never in NED or VM patients (p = 0.013). Conversely, estrogen receptor-positive and HER-2-negative status identified 80 and 95% of bone relapse patients, respectively, but did not discriminate between cases and controls. Conclusions: Our results suggest a pivotal role of CXCR4 expression as a predictor of BM in primary breast cancer. A larger study is ongoing to confirm these results.

show abstract

Section: Discussionmentioning

confidence: 99%

The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Prior studies also showed that the loss of PR is associated with poor prognosis, decreased responsiveness to endocrine therapy, a higher recurrence score with the Oncotype DX test, and a greater chance of bone metastasis. [6][7][8][84][85][86] Indeed, the latest St Gallen guideline proposed that a high Oncotype DX recurrence score is suggestive of luminal B-like subtype. 30 More recent studies using IHC4 assay (ER, PR, HER2, and Ki-67) and Magee Equations have also emphasized the important role of PR levels in ERpositive breast cancer.…”

Section: Ihc-based MC Er-positive Bcmentioning

confidence: 99%

Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update

Tang¹,

Tse

2016

Archives of Pathology &Amp; Laboratory Medicine

Self Cite

131

109

View full text Add to dashboard Cite

Context.-The pioneering works on molecular classification (MC) by Perou and Sorlie et al in the early 2000s using global gene expression profiling identified 5 intrinsic subtypes of invasive breast cancers (IBCs): luminal A, luminal B, normal breast-like, HER2-enriched, and basallike subtypes, each unique in incidence, survival, and response to therapy. Because the application of gene expression profiling in daily practice is not economical or practical at the present time, many investigators have studied the use of immunohistochemical (IHC) surrogates as a substitute for determining the MC of IBC.Objective.-To discuss the continuing efforts that have been made to develop clinically significant and readily available IHC surrogates for the MC of IBC.Data Sources.-Data were obtained from pertinent peer-reviewed English-language literature.Conclusions.-The most commonly used IHC surrogates are estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), dividing IBC into luminal, HER2, and triple-negative subtypes. The addition of Ki-67, cytokeratin 5, and epidermal growth factor receptor (EGFR) separates luminal B from luminal A subtypes, and basal-like subtype from triple-negative breast cancer. More recently, biomarkers such as androgen receptor and p53 have been shown to further stratify these molecular subtypes. Although many studies of IHC-based MC have shown clinical significance similar to gene expression profiling-defined MC, its critical limitations are: (1) a lack of standardization in terminology, (2) a lack of standardization in biomarkers used for each subtype, and (3) the lack of a uniform cutoff for each biomarker. A panel of IHC surrogates for each subtype of IBC is proposed.

show abstract

“…Patients with HR‐positive breast cancer are at increased risk for the development of bone metastases, whereas bone metastases are less frequent in cases of triple‐negative tumors 15, 16, 17, 18, 19, 20, 21. Previous studies also indicated that tumor subtype is an important prognostic factor for the survival of patients with bone metastases, where worse survival was seen in patients with triple‐negative breast cancer 22, 23…”

Section: Introductionmentioning

confidence: 99%

Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis

Gong

Zhang

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

IntroductionPopulation‐based data on the incidence and prognosis of bone metastases at diagnosis of breast cancer are currently limited. Hence, we conducted this study to analyze the incidence proportions and prognostic factors of patients with breast cancer and bone metastases at the time of cancer diagnosis.Materials and methodsPatients with primary invasive breast cancer and bone metastases at initial diagnosis between 2010 and 2014 were identified using the Surveillance, Epidemiology, and End Results (SEER) dataset and Fudan University Shanghai Cancer Center (FUSCC) cohort. Multivariable logistic regression was performed to identify predictors of the presence of bone metastases at diagnosis. Univariate and multivariate analyses were performed to determine the effects of each variable on survival.ResultsOf 229, 195 patients from SEER database included in the analysis, 8295 patients had bone metastases at initial diagnosis, reflecting 3.6% of the entire study population, and 65.1% of the subset with metastatic disease to any distant site. Patients with hormone receptor (HR)‐positive human epidermal growth factor receptor 2 (HER2)‐negative represented the highest incidence proportions among patients with metastatic disease (73.9%). Among entire cohort, multivariable logistic regression identified eight factors as predictors of the presence of bone metastases at diagnosis. Median OS for the patients with bone metastases in SEER and FUSCC cohorts was 30.0 and 68.2 months, respectively. Patients with HR‐positive HER2‐positive subtype had the longest median OS, and patients with triple‐negative subtype showed the shortest median OS. Multivariable Cox model in SEER cohort confirmed age, histology, grade, tumor subtype, extraosseous metastatic sites, history of primary surgery, insurance status, marital status, and income as independent prognostic factors for both OS and BCSS.ConclusionsThe findings of this study provide population‐based estimates of the incidence and prognosis for patients with bone metastases at initial diagnosis of breast cancer.

show abstract

Bone metastasis is strongly associated with estrogen receptor–positive/progesterone receptor–negative breast carcinomas

Cited by 57 publications

References 32 publications

The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study

The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study

Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update

Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis

Contact Info

Product

Resources

About